India-based global pharmaceutical company Lupin Limited (BSE:500257) (NSE:LUPIN) announced on Tuesday that it has received approval from the US Food and Drug Administration (FDA) for its Abbreviated New Drug Application for Dapagliflozin Tablets, 5 mg and 10 mg.
The FDA approved Lupin's Dapagliflozin Tablets, 5 mg and 10 mg, as bioequivalent to Farxiga for the indications in the approved labelling.
Farxiga, a brand of biopharmaceutical company AstraZeneca plc (STO:AZN) (LON:AZN) (NYSE:AZN), is indicated for the treatment of type 2 diabetes, chronic kidney disease, and symptomatic chronic heart failure.
BioArctic and Eisai report FDA extension of Leqembi Iqlik review
Mezzion reveals pre-IND FDA feedback on udenafil development in ADPKD
Altasciences and Certara form strategic partnership to accelerate early drug development
Xbrane resubmits FDA application for ranibizumab biosimilar after facility remediation
European Commission clears first pertuzumab biosimilar in Europe
Vanda Pharmaceuticals reports publication of imsidolimab phase III findings in NEJM Evidence
C-Ray Therapeutics' Copper-64 (Cu-64) Type II DMF gains FDA acceptance